# C. Paul

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/c-paul/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,140 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 92 |
| i10-index | 330 |
| Last Known Institution | Université Fédérale de Toulouse Midi-Pyrénées |
| OpenAlex ID | https://openalex.org/A5082011794 |
| ORCID iD | https://orcid.org/0000-0003-0165-5263 |
| Works | 849 |

## Researcher papers

- [Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis](https://scholariq.org/papers/phase-3-studies-comparing-brodalumab-with-ustekinumab-in-psoriasis/)
- [Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey](https://scholariq.org/papers/patient-perspectives-in-the-management-of-psoriasis-results-from-the-population/)
- [Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)](https://scholariq.org/papers/efficacy-and-safety-of-apremilast-an-oral-phosphodiesterase-4-inhibitor-in/)
- [ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children](https://scholariq.org/papers/etfad-eadv-eczema-task-force-2020-position-paper-on-diagnosis-and-treatment-of/)
- [Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis](https://scholariq.org/papers/abrocitinib-versus-placebo-or-dupilumab-for-atopic-dermatitis/)
- [Bimekizumab versus Secukinumab in Plaque Psoriasis](https://scholariq.org/papers/bimekizumab-versus-secukinumab-in-plaque-psoriasis/)
- [Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials](https://scholariq.org/papers/secukinumab-in-moderate-to-severe-hidradenitis-suppurativa-sunshine-and-sunrise/)
- [Prevalence of most common skin diseases in Europe: a population‐based study](https://scholariq.org/papers/prevalence-of-most-common-skin-diseases-in-europe-a-population-based-study/)
- [Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting](https://scholariq.org/papers/towards-global-consensus-on-outcome-measures-for-atopic-eczema-research-results/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions-2/)

## Researcher university

- [Université Fédérale de Toulouse Midi-Pyrénées](https://scholariq.org/institutions/universite-federale-de-toulouse-midi-pyrenees/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.